A nonenzimatikus glikációs végtermékek képződése szerepet játszik a diabeteses szövődmények, az arteriosclerosis, a krónikus veseelégtelenséghez kapcsolódó kötőszöveti degeneratív folyamatok patogenezisében. A szisztémás AGE-lerakódás részeként a bőrben jelen lévő fluoreszcens természetű molekulák vizsgálatára az elmúlt években egy noninvazív, mobil mérőeszközt fejlesztettek ki. Ennek segítségével a páciensek kumulatív metabolikus terhelése néhány perc alatt mérhető. A bőr-autofluoreszcencia-mérés szórása 10%-on belüli, cardiovascularis eseményekre vonatkozó prediktivitása még a veseelégtelen betegek csoportjában is meghaladja a konvencionális glykaemiás markerek pontosságát. A diabetes korai fázisában hatékony szűrőmódszer, már diagnosztizált diabetes esetén a micro- és macrovascularis szövődmények kialakulását jelzi. Az autofluoreszcenciát befolyásoló kórképekben (szisztémás autoimmun betegség, generalizált bőrgyógyászati kórképek, icterust okozó hepatobiliaris folyamatok) nem használható a módszer. Az érfali struktúrfehérjék glikációja miatt szoros korrelációt találtak az artériás rendszer rigiditásának fokozódását jelző pulzushullám-terjedési sebesség változásával. Orv. Hetil., 2012, 153, 1651–1657.
Meerwaldt, R., Zeebregts, C. J., Navis, G., et al.: Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am. J. Kidney Dis., 2009, 53, 138–150.
Navis G. , 'Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis ' (2009 ) 53 Am. J. Kidney Dis. : 138 -150.
Meerwaldt, R., Hartog, J. W., Graaff, R., et al.: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol., 2005, 16, 3687–3693.
Graaff R. , 'Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients ' (2005 ) 16 J. Am. Soc. Nephrol. : 3687 -3693.
Kender, Z., Torzsa, P., Grolmusz, K. V., et al.: The role of methylglyoxal metabolism in type-2 diabetes and its complications. [A metilglioxál-metabolizmus szerepe 2-es típusú cukorbetegségben és szövődményeiben.] Orv. Hetil., 2012, 153, 574–585. [Hungarian]
Grolmusz K. V. , 'The role of methylglyoxal metabolism in type-2 diabetes and its complications. [A metilglioxál-metabolizmus szerepe 2-es típusú cukorbetegségben és szövődményeiben.] ' (2012 ) 153 Orv. Hetil. : 574 -585.
Lutgers, H. L., Gerrits, E. G., Graaff, R., et al.: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia, 2009, 52, 789–797.
Graaff R. , 'Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus ' (2009 ) 52 Diabetologia : 789 -797.
Felipe, D. L., Hempe, J. M., Liu, S., et al.: Skin intrinsic fluorescence is associated with hemoglobin A(1c) and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes. Diabetes Care, 2011, 34, 1816–1820.
Liu S. , 'Skin intrinsic fluorescence is associated with hemoglobin A(1c) and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes ' (2011 ) 34 Diabetes Care : 1816 -1820.
Noordzij, M. J., Lefrandt, J. D., Graaff, R., et al.: Skin autofluorescence and glycemic variability. Diabetes Technol. Ther., 2010, 12, 581–585.
Graaff R. , 'Skin autofluorescence and glycemic variability ' (2010 ) 12 Diabetes Technol. Ther. : 581 -585.
Gerrits, E. G., Lutgers, H. L., Kleefstra, N., et al.: Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9). J. Diabetes Sci. Technol., 2008, 2, 572–577.
Kleefstra N. , 'Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9) ' (2008 ) 2 J. Diabetes Sci. Technol. : 572 -577.
Okada, T., Nakao, T., Matsumoto, H., et al.: Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern. Med., 2007, 46, 807–814.
Matsumoto H. , 'Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease ' (2007 ) 46 Intern. Med. : 807 -814.
Maynard, J. D., Rohrscheib, M., Way, J. F., et al.: Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care, 2007, 30, 1120–1124.
Way J. F. , 'Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C ' (2007 ) 30 Diabetes Care : 1120 -1124.
Lutgers, H. L., Graaff, R., Links, T. P., et al.: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care, 2006, 29, 2654–2659.
Links T. P. , 'Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes ' (2006 ) 29 Diabetes Care : 2654 -2659.
Gerrits, E. G., Lutgers, H. L., Kleefstra, N., et al.: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care, 2008, 31, 517–521.
Kleefstra N. , 'Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications ' (2008 ) 31 Diabetes Care : 517 -521.
Meerwaldt, R., Lutgers, H. L., Links, T. P., et al.: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care, 2007, 30, 107–112.
Links T. P. , 'Skin autofluorescence is a strong predictor of cardiac mortality in diabetes ' (2007 ) 30 Diabetes Care : 107 -112.
Mulder, D. J., van Haelst, P. L., Graaff, R., et al.: Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth. Heart J., 2009, 17, 162–168.
Graaff R. , 'Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events ' (2009 ) 17 Neth. Heart J. : 162 -168.
Hu, H., Han, C. M., Hu, X. L., et al.: Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects. J. Zhejiang Univ. Sci. B., 2012, 13, 372–377.
Hu X. L. , 'Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects ' (2012 ) 13 J. Zhejiang Univ. Sci. B. : 372 -377.
Meerwaldt, R., Zeebregts, C. J., Navis, G., et al.: Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am. J. Kidney Dis., 2009, 53, 138–150.
Navis G. , 'Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis ' (2009 ) 53 Am. J. Kidney Dis. : 138 -150.
Meerwaldt, R., Hartog, J. W., Graaff, R., et al.: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol., 2005, 16, 3687–3693.
Graaff R. , 'Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients ' (2005 ) 16 J. Am. Soc. Nephrol. : 3687 -3693.
Oleniuc, M., Schiller, A., Secara, I., et al.: Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. Int. Urol. Nephrol., 2011. Dec. 10. [Epub ahead of print], DOI:10.1007/s11255-011-0097-5
Arsov, S., Graaff, R., Morariu, A. M., et al.: Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? Nephrol. Dial. Transplant., 2010, 25, 885–891.
Morariu A. M. , 'Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? ' (2010 ) 25 Nephrol. Dial. Transplant. : 885 -891.
De Vriese, A. S., Tilton, R. G., Mortier, S., et al.: Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol. Dial. Transplant., 2006, 21, 2549–2555.
Mortier S. , 'Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia ' (2006 ) 21 Nephrol. Dial. Transplant. : 2549 -2555.
McIntyre, N. J., Chesterton, L. J., John, S. G., et al.: Tissue-advanced glycation end product concentration in dialysis patients. Clin. J. Am. Soc. Nephrol., 2010, 5, 51–55.
John S. G. , 'Tissue-advanced glycation end product concentration in dialysis patients ' (2010 ) 5 Clin. J. Am. Soc. Nephrol. : 51 -55.
Pešić, I., Dihazi, G. H., Müller, G. A., et al.: Short-term increase of glucose concentration in PDS results in extensive removal and high glycation level of vital proteins during continuous ambulatory peritoneal dialysis. Nephrol. Dial. Transplant., 2011, 26, 2674–2683.
Müller G. A. , 'Short-term increase of glucose concentration in PDS results in extensive removal and high glycation level of vital proteins during continuous ambulatory peritoneal dialysis ' (2011 ) 26 Nephrol. Dial. Transplant. : 2674 -2683.
Gerrits, E. G., Smit, A. J., Bilo, H. J.: AGEs, autofluorescence and renal function. Nephrol. Dial. Transplant., 2009, 24, 710–713.
Bilo H. J. , 'AGEs, autofluorescence and renal function ' (2009 ) 24 Nephrol. Dial. Transplant. : 710 -713.
Ueno, H., Koyama, H., Tanaka, S., et al.: Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism, 2008, 57, 1452–1457.
Tanaka S. , 'Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease ' (2008 ) 57 Metabolism : 1452 -1457.
Tanaka, K., Tani, Y, Asai, J., et al.: Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet. Med., 2012, 29, 492–500.
Asai J. , 'Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes ' (2012 ) 29 Diabet. Med. : 492 -500.
Watfa, G., Soulis, G., Tartagni, E., et al.: Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. Diabetes Metab., 2012 Jun 13. [Epub ahead of print], DOI:10.1016/j.diabet.2012.04.004
Januszewski, A. S., Sachithanandan, N., Karschimkus, C., et al.: Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet. Med., 2012, 29, 726–733.
Karschimkus C. , 'Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction ' (2012 ) 29 Diabet. Med. : 726 -733.
Hofmann, B., Adam, A. C., Jacobs, K., et al.: Advanced glycation end product associated skin autofluorescence: A mirror of vascular function? Exp. Gerontol., 2012 May 12. [Epub ahead of print], DOI:10.1016/j.exger.2012.04.011
Ohnuki, Y., Nagano, R., Takizawa, S., et al.: Advanced glycation end products in patients with cerebral infarction. Intern. Med., 2009, 48, 587–591.
Takizawa S. , 'Advanced glycation end products in patients with cerebral infarction ' (2009 ) 48 Intern. Med. : 587 -591.
Kakuta, T., Tanaka, R., Hyodo, T., et al.: Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am. J. Kidney Dis., 2011, 57, 422–431.
Hyodo T. , 'Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients ' (2011 ) 57 Am. J. Kidney Dis. : 422 -431.
Di Iorio, B., Bellasi, A., Russo, D., INDEPENDENT study investigators: Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin. J. Am. Soc. Nephrol., 2012, 7, 487–493.
Russo D. , 'Mortality in kidney disease patients treated with phosphate binders: a randomized study ' (2012 ) 7 Clin. J. Am. Soc. Nephrol. : 487 -493.
Vlassara, H., Uribarri, J., Cai, W., et al.: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin. J. Am. Soc. Nephrol., 2012, 7, 934–942.
Cai W. , 'Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease ' (2012 ) 7 Clin. J. Am. Soc. Nephrol. : 934 -942.
McIntyre, N. J., Fluck, R. J., McIntyre, C. W., et al.: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin. J. Am. Soc. Nephrol., 2011, 6, 2356–2363.
McIntyre C. W. , 'Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3 ' (2011 ) 6 Clin. J. Am. Soc. Nephrol. : 2356 -2363.
Beisswenger, P. J.: Glycation and biomarkers of vascular complications of diabetes. Amino Acids, 2012, 42, 1171–1183.
Beisswenger P. J. , 'Glycation and biomarkers of vascular complications of diabetes ' (2012 ) 42 Amino Acids : 1171 -1183.
Lyons, T. J., Basu, A.: Biomarkers in diabetes: hemoglobin-A1c, vascular and tissue markers. Transl. Res., 2012, 159, 303–312.
Basu A. , 'Biomarkers in diabetes: hemoglobin-A1c, vascular and tissue markers ' (2012 ) 159 Transl. Res. : 303 -312.